Steering the course of CAR T cell therapy with lipid nanoparticles

作者：Muhammad Babar Khawar, Ali Afzal, Yue Si, Haibo Sun · 发表于：Journal of Nanobiotechnology · 年份：2024 · DOI：10.1186/s12951-024-02630-1 · 被引用次数：44 · 研究领域：CAR-T cell therapy research、Viral Infectious Diseases and Gene Expression in Insects、Nanowire Synthesis and Applications

Lipid nanoparticles (LNPs) have proven themselves as transformative actors in chimeric antigen receptor (CAR) T cell therapy, surpassing traditional methods and addressing challenges like immunogenicity, reduced toxicity, and improved safety. Promising preclinical results signal a shift toward safer and more effective CAR T cell treatments. Ongoing research aims to validate these findings in clinical trials, marking a new era guided by LNPs utility in CAR therapy. Herein, we explore the preference for LNPs over traditional methods, highlighting the versatility of LNPs and their effective delivery of nucleic acids. Additionally, we address key challenges in clinical considerations, heralding a new era in CAR T cell therapy.